Kang Xingyu, Huang Ying, Lv Xueyan, Liu Xiaofang, Chen Siyu, Ma Le, Shi Shuai
Graduate School, Heilongjiang University of Chinese Medicine, Harbin, China.
Oncology Department, The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
Front Neurol. 2024 Dec 18;15:1459738. doi: 10.3389/fneur.2024.1459738. eCollection 2024.
This study aimed to systematically evaluate the clinical efficacy of Jingjin (muscle region of the meridian, sinew/tendon/fascia) acupuncture therapy in treating peripheral facial paralysis.
A computerized search of PubMed, EMBASE, Cochrane Central Register of Controlled Clinical Studies, SCOPUS, Web of Science, PEDro, China Knowledge, Wanfang, and Wipu databases was performed for published randomized controlled trials (RCTs) on the treatment of peripheral facial paralysis using Jingjin acupuncture therapy from the beginning of the construction of the databases until 2 April 2024. After a two-person independent extraction of data, the studies were assessed for paper quality and then analyzed for meta-analysis using RevMan5.4 software.
A total of 19 randomized controlled trials involving 1,436 patients were included. Meta-analysis showed that Jingjin acupuncture therapy for peripheral facial palsy had a higher overall effectiveness rate (OR = 3.93, 95% CI [2.78, 5.56], Z = 7.75, < 0.00001), and cure rates (RR = 1.69, 95% CI [1.51, 1.90], and Z = 8.89, < 0.00001) were higher than those of conventional therapy. Jingjin acupuncture therapy was also superior to conventional acupuncture therapy in terms of Facial Disability Index-Physical (FDIP) scores, Facial Disability Index-Social (FDIS) scores, facial nerve function scores, and Portmann scores on the Facial Disability Index Scale in patients with peripheral facial paralysis.
Jingjin acupuncture therapy is effective in treating peripheral facial paralysis and has better overall efficacy than conventional therapy. However, the reliability is limited by the small number of high-quality studies with scientifically rigorous methods and designs, so more large-sample, high-quality, randomized controlled studies are still needed for further validation.
https://www.crd.york.ac.uk/prospero/, Identifier CRD42024543195.
本研究旨在系统评价经筋针刺疗法治疗周围性面瘫的临床疗效。
对PubMed、EMBASE、Cochrane临床对照试验中心注册库、SCOPUS、Web of Science、PEDro、中国知网、万方和维普数据库进行计算机检索,查找从数据库建库至2024年4月2日期间发表的关于经筋针刺疗法治疗周围性面瘫的随机对照试验(RCT)。经过两人独立的数据提取后,对研究进行论文质量评估,然后使用RevMan5.4软件进行荟萃分析。
共纳入19项随机对照试验,涉及1436例患者。荟萃分析表明,经筋针刺疗法治疗周围性面瘫的总有效率更高(OR = 3.93,95%CI[2.78, 5.56],Z = 7.75,P < 0.00001),治愈率(RR = 1.69,95%CI[1.51, 1.90],Z = 8.89,P < 0.00001)高于传统疗法。在周围性面瘫患者的面部残疾指数-身体(FDIP)评分、面部残疾指数-社会(FDIS)评分、面神经功能评分和面部残疾指数量表上的波特曼评分方面,经筋针刺疗法也优于传统针刺疗法。
经筋针刺疗法治疗周围性面瘫有效,总体疗效优于传统疗法。然而,由于采用科学严谨方法和设计的高质量研究数量较少,其可靠性受到限制,因此仍需要更多大样本、高质量的随机对照研究进行进一步验证。